Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Conditions:   GM2 Gangliosidosis;   Niemann-Pick Disease, Type C Interventions:   Drug: AZ-3102 (Dose 1);   Drug: Placebo;   Drug: AZ-3102 (Dose 2) Sponsor:   Azafaros A.G. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials